What is Natera, Inc.'s P/E and P/B ratio?

Natera, Inc. has a P/E ratio of -297.3 and a P/B ratio of 31.76.

What is Natera, Inc.'s debt-to-equity ratio?

Natera, Inc. has a debt-to-equity ratio of 0.13.

How much does Natera, Inc. owe compared with what it owns?

Natera, Inc. owes $0.31 for every $1 it owns (balance sheet Jun 2026), which is low.

Does Natera, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Natera, Inc..

Where can I read the latest news about Natera, Inc.?

Recent headlines about Natera, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Natera, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Natera, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

Natera, Inc. (NTRA) Stock Price Analysis

Q: What is Natera, Inc.'s Positivity rank?

Natera, Inc. is ranked #6,201 of 6,774 companies globally and #3,530 of 4,000 in United States on PositoAI, with a Positivity Score of 3,212.

Natera, Inc. — Overview & Financial Snapshot

Natera, Inc. (NasdaqGS: NTRA) is a Healthcare company, ranked #6,201 of 6,774 companies globally and #3,530 of 4,000 in United States on PositoAI, with a Positivity Score of 3,212. Its market capitalisation is ₹5.46 lakh Cr ($57.86B), P/E ratio is -297.3 and P/B ratio is 31.76. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Powered by OpenAI

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Natera, Inc.